Home Healthcare IT Global Radioligand Therapy Market Size, Demand, Opportunities, Forecast by 2033

Radioligand Therapy Market Size & Outlook, 2025-2033

Radioligand Therapy Market Size, Share & Trends Analysis Report By Isotope (Lutetium-177 (Lu-177), Actinium-225 (Ac-225), Iodine-131 (I-131), Other Isotopes), By Target (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor), By Indication (Prostate Cancer, Neuroendocrine Tumours (NETs), Others), By End-User (Hospitals, Ambulatory Surgical Centers, Cancer Treatment Centers, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRHI1832DR
Last Updated : May, 2025
Pages : 110
Author : Debashree Bora
Format : PDF, Excel

Market Segmentation

  1. Radioligand Therapy Market, By Isotope (2021-2033)
    1. Lutetium-177 (Lu-177)
    2. Actinium-225 (Ac-225)
    3. Iodine-131 (I-131)
    4. Other Isotopes
  2. Radioligand Therapy Market, By Target (2021-2033)
    1. Prostate-Specific Membrane Antigen
    2. Ki 67 Expression and Grading
    3. Cytochrome P450 17A1 Inhibitor
  3. Radioligand Therapy Market, By Indication (2021-2033)
    1. Prostate Cancer
    2. Neuroendocrine Tumours (NETs)
    3. Others
  4. Radioligand Therapy Market, By End-User (2021-2033)
    1. Hospitals
    2. Ambulatory Surgical Centers
    3. Cancer Treatment Centers
    4. Others
    1. North America
      1. North America Radioligand Therapy Market, By Isotope
        1. Lutetium-177 (Lu-177)
          1. Actinium-225 (Ac-225)
            1. Iodine-131 (I-131)
              1. Other Isotopes
              2. North America Radioligand Therapy Market, By Target
                1. Prostate-Specific Membrane Antigen
                  1. Ki 67 Expression and Grading
                    1. Cytochrome P450 17A1 Inhibitor
                    2. North America Radioligand Therapy Market, By Indication
                      1. Prostate Cancer
                        1. Neuroendocrine Tumours (NETs)
                          1. Others
                          2. North America Radioligand Therapy Market, By End-User
                            1. Hospitals
                              1. Ambulatory Surgical Centers
                                1. Cancer Treatment Centers
                                  1. Others
                                  2. U.S.
                                    1. U.S. Radioligand Therapy Market, By Isotope
                                      1. Lutetium-177 (Lu-177)
                                        1. Actinium-225 (Ac-225)
                                          1. Iodine-131 (I-131)
                                            1. Other Isotopes
                                            2. U.S. Radioligand Therapy Market, By Target
                                              1. Prostate-Specific Membrane Antigen
                                                1. Ki 67 Expression and Grading
                                                  1. Cytochrome P450 17A1 Inhibitor
                                                  2. U.S. Radioligand Therapy Market, By Indication
                                                    1. Prostate Cancer
                                                      1. Neuroendocrine Tumours (NETs)
                                                        1. Others
                                                        2. U.S. Radioligand Therapy Market, By End-User
                                                          1. Hospitals
                                                            1. Ambulatory Surgical Centers
                                                              1. Cancer Treatment Centers
                                                                1. Others
                                                              2. Canada
                                                            2. Europe
                                                              1. Europe Radioligand Therapy Market, By Isotope
                                                                1. Lutetium-177 (Lu-177)
                                                                  1. Actinium-225 (Ac-225)
                                                                    1. Iodine-131 (I-131)
                                                                      1. Other Isotopes
                                                                      2. Europe Radioligand Therapy Market, By Target
                                                                        1. Prostate-Specific Membrane Antigen
                                                                          1. Ki 67 Expression and Grading
                                                                            1. Cytochrome P450 17A1 Inhibitor
                                                                            2. Europe Radioligand Therapy Market, By Indication
                                                                              1. Prostate Cancer
                                                                                1. Neuroendocrine Tumours (NETs)
                                                                                  1. Others
                                                                                  2. Europe Radioligand Therapy Market, By End-User
                                                                                    1. Hospitals
                                                                                      1. Ambulatory Surgical Centers
                                                                                        1. Cancer Treatment Centers
                                                                                          1. Others
                                                                                          2. U.K.
                                                                                            1. U.K. Radioligand Therapy Market, By Isotope
                                                                                              1. Lutetium-177 (Lu-177)
                                                                                                1. Actinium-225 (Ac-225)
                                                                                                  1. Iodine-131 (I-131)
                                                                                                    1. Other Isotopes
                                                                                                    2. U.K. Radioligand Therapy Market, By Target
                                                                                                      1. Prostate-Specific Membrane Antigen
                                                                                                        1. Ki 67 Expression and Grading
                                                                                                          1. Cytochrome P450 17A1 Inhibitor
                                                                                                          2. U.K. Radioligand Therapy Market, By Indication
                                                                                                            1. Prostate Cancer
                                                                                                              1. Neuroendocrine Tumours (NETs)
                                                                                                                1. Others
                                                                                                                2. U.K. Radioligand Therapy Market, By End-User
                                                                                                                  1. Hospitals
                                                                                                                    1. Ambulatory Surgical Centers
                                                                                                                      1. Cancer Treatment Centers
                                                                                                                        1. Others
                                                                                                                      2. Germany
                                                                                                                      3. France
                                                                                                                      4. Spain
                                                                                                                      5. Italy
                                                                                                                      6. Russia
                                                                                                                      7. Nordic
                                                                                                                      8. Benelux
                                                                                                                      9. Rest of Europe
                                                                                                                    2. APAC
                                                                                                                      1. APAC Radioligand Therapy Market, By Isotope
                                                                                                                        1. Lutetium-177 (Lu-177)
                                                                                                                          1. Actinium-225 (Ac-225)
                                                                                                                            1. Iodine-131 (I-131)
                                                                                                                              1. Other Isotopes
                                                                                                                              2. APAC Radioligand Therapy Market, By Target
                                                                                                                                1. Prostate-Specific Membrane Antigen
                                                                                                                                  1. Ki 67 Expression and Grading
                                                                                                                                    1. Cytochrome P450 17A1 Inhibitor
                                                                                                                                    2. APAC Radioligand Therapy Market, By Indication
                                                                                                                                      1. Prostate Cancer
                                                                                                                                        1. Neuroendocrine Tumours (NETs)
                                                                                                                                          1. Others
                                                                                                                                          2. APAC Radioligand Therapy Market, By End-User
                                                                                                                                            1. Hospitals
                                                                                                                                              1. Ambulatory Surgical Centers
                                                                                                                                                1. Cancer Treatment Centers
                                                                                                                                                  1. Others
                                                                                                                                                  2. China
                                                                                                                                                    1. China Radioligand Therapy Market, By Isotope
                                                                                                                                                      1. Lutetium-177 (Lu-177)
                                                                                                                                                        1. Actinium-225 (Ac-225)
                                                                                                                                                          1. Iodine-131 (I-131)
                                                                                                                                                            1. Other Isotopes
                                                                                                                                                            2. China Radioligand Therapy Market, By Target
                                                                                                                                                              1. Prostate-Specific Membrane Antigen
                                                                                                                                                                1. Ki 67 Expression and Grading
                                                                                                                                                                  1. Cytochrome P450 17A1 Inhibitor
                                                                                                                                                                  2. China Radioligand Therapy Market, By Indication
                                                                                                                                                                    1. Prostate Cancer
                                                                                                                                                                      1. Neuroendocrine Tumours (NETs)
                                                                                                                                                                        1. Others
                                                                                                                                                                        2. China Radioligand Therapy Market, By End-User
                                                                                                                                                                          1. Hospitals
                                                                                                                                                                            1. Ambulatory Surgical Centers
                                                                                                                                                                              1. Cancer Treatment Centers
                                                                                                                                                                                1. Others
                                                                                                                                                                              2. Korea
                                                                                                                                                                              3. Japan
                                                                                                                                                                              4. India
                                                                                                                                                                              5. Australia
                                                                                                                                                                              6. Taiwan
                                                                                                                                                                              7. South East Asia
                                                                                                                                                                              8. Rest of Asia-Pacific
                                                                                                                                                                            2. Middle East and Africa
                                                                                                                                                                              1. Middle East and Africa Radioligand Therapy Market, By Isotope
                                                                                                                                                                                1. Lutetium-177 (Lu-177)
                                                                                                                                                                                  1. Actinium-225 (Ac-225)
                                                                                                                                                                                    1. Iodine-131 (I-131)
                                                                                                                                                                                      1. Other Isotopes
                                                                                                                                                                                      2. Middle East and Africa Radioligand Therapy Market, By Target
                                                                                                                                                                                        1. Prostate-Specific Membrane Antigen
                                                                                                                                                                                          1. Ki 67 Expression and Grading
                                                                                                                                                                                            1. Cytochrome P450 17A1 Inhibitor
                                                                                                                                                                                            2. Middle East and Africa Radioligand Therapy Market, By Indication
                                                                                                                                                                                              1. Prostate Cancer
                                                                                                                                                                                                1. Neuroendocrine Tumours (NETs)
                                                                                                                                                                                                  1. Others
                                                                                                                                                                                                  2. Middle East and Africa Radioligand Therapy Market, By End-User
                                                                                                                                                                                                    1. Hospitals
                                                                                                                                                                                                      1. Ambulatory Surgical Centers
                                                                                                                                                                                                        1. Cancer Treatment Centers
                                                                                                                                                                                                          1. Others
                                                                                                                                                                                                          2. UAE
                                                                                                                                                                                                            1. UAE Radioligand Therapy Market, By Isotope
                                                                                                                                                                                                              1. Lutetium-177 (Lu-177)
                                                                                                                                                                                                                1. Actinium-225 (Ac-225)
                                                                                                                                                                                                                  1. Iodine-131 (I-131)
                                                                                                                                                                                                                    1. Other Isotopes
                                                                                                                                                                                                                    2. UAE Radioligand Therapy Market, By Target
                                                                                                                                                                                                                      1. Prostate-Specific Membrane Antigen
                                                                                                                                                                                                                        1. Ki 67 Expression and Grading
                                                                                                                                                                                                                          1. Cytochrome P450 17A1 Inhibitor
                                                                                                                                                                                                                          2. UAE Radioligand Therapy Market, By Indication
                                                                                                                                                                                                                            1. Prostate Cancer
                                                                                                                                                                                                                              1. Neuroendocrine Tumours (NETs)
                                                                                                                                                                                                                                1. Others
                                                                                                                                                                                                                                2. UAE Radioligand Therapy Market, By End-User
                                                                                                                                                                                                                                  1. Hospitals
                                                                                                                                                                                                                                    1. Ambulatory Surgical Centers
                                                                                                                                                                                                                                      1. Cancer Treatment Centers
                                                                                                                                                                                                                                        1. Others
                                                                                                                                                                                                                                      2. Turkey
                                                                                                                                                                                                                                      3. Saudi Arabia
                                                                                                                                                                                                                                      4. South Africa
                                                                                                                                                                                                                                      5. Egypt
                                                                                                                                                                                                                                      6. Nigeria
                                                                                                                                                                                                                                      7. Rest of MEA
                                                                                                                                                                                                                                    2. LATAM
                                                                                                                                                                                                                                      1. LATAM Radioligand Therapy Market, By Isotope
                                                                                                                                                                                                                                        1. Lutetium-177 (Lu-177)
                                                                                                                                                                                                                                          1. Actinium-225 (Ac-225)
                                                                                                                                                                                                                                            1. Iodine-131 (I-131)
                                                                                                                                                                                                                                              1. Other Isotopes
                                                                                                                                                                                                                                              2. LATAM Radioligand Therapy Market, By Target
                                                                                                                                                                                                                                                1. Prostate-Specific Membrane Antigen
                                                                                                                                                                                                                                                  1. Ki 67 Expression and Grading
                                                                                                                                                                                                                                                    1. Cytochrome P450 17A1 Inhibitor
                                                                                                                                                                                                                                                    2. LATAM Radioligand Therapy Market, By Indication
                                                                                                                                                                                                                                                      1. Prostate Cancer
                                                                                                                                                                                                                                                        1. Neuroendocrine Tumours (NETs)
                                                                                                                                                                                                                                                          1. Others
                                                                                                                                                                                                                                                          2. LATAM Radioligand Therapy Market, By End-User
                                                                                                                                                                                                                                                            1. Hospitals
                                                                                                                                                                                                                                                              1. Ambulatory Surgical Centers
                                                                                                                                                                                                                                                                1. Cancer Treatment Centers
                                                                                                                                                                                                                                                                  1. Others
                                                                                                                                                                                                                                                                  2. Brazil
                                                                                                                                                                                                                                                                    1. Brazil Radioligand Therapy Market, By Isotope
                                                                                                                                                                                                                                                                      1. Lutetium-177 (Lu-177)
                                                                                                                                                                                                                                                                        1. Actinium-225 (Ac-225)
                                                                                                                                                                                                                                                                          1. Iodine-131 (I-131)
                                                                                                                                                                                                                                                                            1. Other Isotopes
                                                                                                                                                                                                                                                                            2. Brazil Radioligand Therapy Market, By Target
                                                                                                                                                                                                                                                                              1. Prostate-Specific Membrane Antigen
                                                                                                                                                                                                                                                                                1. Ki 67 Expression and Grading
                                                                                                                                                                                                                                                                                  1. Cytochrome P450 17A1 Inhibitor
                                                                                                                                                                                                                                                                                  2. Brazil Radioligand Therapy Market, By Indication
                                                                                                                                                                                                                                                                                    1. Prostate Cancer
                                                                                                                                                                                                                                                                                      1. Neuroendocrine Tumours (NETs)
                                                                                                                                                                                                                                                                                        1. Others
                                                                                                                                                                                                                                                                                        2. Brazil Radioligand Therapy Market, By End-User
                                                                                                                                                                                                                                                                                          1. Hospitals
                                                                                                                                                                                                                                                                                            1. Ambulatory Surgical Centers
                                                                                                                                                                                                                                                                                              1. Cancer Treatment Centers
                                                                                                                                                                                                                                                                                                1. Others
                                                                                                                                                                                                                                                                                              2. Mexico
                                                                                                                                                                                                                                                                                              3. Argentina
                                                                                                                                                                                                                                                                                              4. Chile
                                                                                                                                                                                                                                                                                              5. Colombia
                                                                                                                                                                                                                                                                                              6. Rest of LATAM

                                                                                                                                                                                                                                                                                          Available for purchase with detailed segment data, forecasts, and regional insights.

                                                                                                                                                                                                                                                                                          Get This Report

                                                                                                                                                                                                                                                                                          Download Free Sample

                                                                                                                                                                                                                                                                                          Note: Please ensure you provide an active email address as we will be sending sample details via email.
                                                                                                                                                                                                                                                                                          The button will be active once the above form is filled

                                                                                                                                                                                                                                                                                          Our Clients:

                                                                                                                                                                                                                                                                                          LG Electronics
                                                                                                                                                                                                                                                                                          AMCAD Engineering
                                                                                                                                                                                                                                                                                          KOBE STEEL LTD.
                                                                                                                                                                                                                                                                                          Hindustan National Glass & Industries Limited
                                                                                                                                                                                                                                                                                          Voith Group
                                                                                                                                                                                                                                                                                          International Paper
                                                                                                                                                                                                                                                                                          Hansol Paper
                                                                                                                                                                                                                                                                                          Whirlpool Corporation
                                                                                                                                                                                                                                                                                          Sony
                                                                                                                                                                                                                                                                                          Samsung Electronics
                                                                                                                                                                                                                                                                                          Qualcomm
                                                                                                                                                                                                                                                                                          Google
                                                                                                                                                                                                                                                                                          Fiserv
                                                                                                                                                                                                                                                                                          Veto-Pharma
                                                                                                                                                                                                                                                                                          Nippon Becton Dickinson
                                                                                                                                                                                                                                                                                          Merck
                                                                                                                                                                                                                                                                                          Argon Medical Devices
                                                                                                                                                                                                                                                                                          Abbott
                                                                                                                                                                                                                                                                                          Ajinomoto
                                                                                                                                                                                                                                                                                          Denon
                                                                                                                                                                                                                                                                                          Doosan
                                                                                                                                                                                                                                                                                          Meiji Seika Kaisha Ltd
                                                                                                                                                                                                                                                                                          LG Chemicals
                                                                                                                                                                                                                                                                                          LCY chemical group
                                                                                                                                                                                                                                                                                          Bayer
                                                                                                                                                                                                                                                                                          Airrane
                                                                                                                                                                                                                                                                                          BASF
                                                                                                                                                                                                                                                                                          Toyota Industries
                                                                                                                                                                                                                                                                                          Nissan Motors
                                                                                                                                                                                                                                                                                          Neenah
                                                                                                                                                                                                                                                                                          Mitsubishi
                                                                                                                                                                                                                                                                                          Hyundai Motor Company

                                                                                                                                                                                                                                                                                          We are featured on :

                                                                                                                                                                                                                                                                                          Address:
                                                                                                                                                                                                                                                                                          Office 515 A, Amanora Chambers,
                                                                                                                                                                                                                                                                                          Amanora Park Town, Hadapsar,
                                                                                                                                                                                                                                                                                          Pune 411028, Maharashtra, India.
                                                                                                                                                                                                                                                                                          Contact Us:
                                                                                                                                                                                                                                                                                          +1 646 905 0080 (U.S.)
                                                                                                                                                                                                                                                                                          +91 8087085354 (India)
                                                                                                                                                                                                                                                                                          +44 203 695 0070 (U.K.)

                                                                                                                                                                                                                                                                                          sales@straitsresearch.com

                                                                                                                                                                                                                                                                                          Quick Links
                                                                                                                                                                                                                                                                                          Help
                                                                                                                                                                                                                                                                                          Verified. Protected. Secure.
                                                                                                                                                                                                                                                                                          DMCA.com Protection Status
                                                                                                                                                                                                                                                                                          Secure Payments:
                                                                                                                                                                                                                                                                                          Follow Us:
                                                                                                                                                                                                                                                                                          www.straitsresearch.com © Copyright . All rights Reserved.